Involvement of hepcidin in the anemia of multiple myeloma

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3262-3267

  Sharma, Sanjai ^a,d   Nemeth, Elizabeta ^a   Chen, Yi Hsiang ^b   Goodnough, Julia ^a   Huston, Alissa ^c   Roodman, G D ^c   Ganz, Tomas ^a   Lichtenstein, Alan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; ANTIMICROBIAL CATIONIC PEPTIDE;

ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; UPREGULATION; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URINE;

ANEMIA; ANTIMICROBIAL CATIONIC PEPTIDES; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FERRITINS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MULTIPLE MYELOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 50349085287     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4153     Document Type: Article

References (33)

1. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975;50:29-40.
2. Mittelman M. The implications of anemia in multiple myeloma. Clin Lymphoma 2003;4 Suppl 1:S23-9.
3. Musto P. Falcone A, DArena G, et al. Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis. Eur J Haematol 1997;58:314-9.
4. Roodman GD, Horadam VW, Wright TL. Inhibition of erythroid colony formation by autologous bone marrow adherent cells from patients with the anemia of chronic disease. Blood 1983;62:406-12.
5. Silvestris F, Cafforio P, Tucci M, Dammacco F. Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 2002;99:1305-13.
6. Dallalio G, Law E, Means RT, Jr. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 2006:107:2702-4.
7. Nemeth E,Valore EV,Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003:101:2461 -3.
8. GanzT. Molecular pathogenesis of anemia of chronic disease. Pediatr Blood Cancer 2006;46:554-7.
9. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306: 2090-3.
10. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271 -6.
11. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A 2005;102:1906-10.
12. Klein B, Zhang XG, Jourdan M, et al. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw 1990; 1: 193-201.
13. Nachbaur DM, Herold M, Maneschg A, Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol 1991;62:54-8.
14. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
15. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001:29:45.
16. Pak M, Lopez MA, Gabayan V, GanzT, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006;108:3730-5.
17. Lichtenstein A, Berenson J, Norman D, Chang MP, Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 1989;74:1266-73.
18. Xiong Y, Donavan KA, Kline MP et al. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of inter- leukin-1. J Interferon Cytokine Res 2006;26:83-95.
19. Donovan KA, Lacy MQ, Gertz MA, Lust JA. IL-1 p expression in IgM monoclonal gammopathy and its relationship to multiple myeloma. Leukemia 2002;16:382-5.
20. Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest 2005;115:2180-6.
21. Inamura J, Ikuta K, Jimbo J, et al. Upregulation of hepcidin by interleukin-1 (ß in human hepatoma cell lines. Hepatol Res 2005;33:198-205.
22. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999;29:3945-50.
23. Nicolas G, Bennoun M, Porteu A, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A 2002;99:4596-601.
24. Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 2005;105:1797-802.
25. Roy CN, Mak HH, Akpan I, Losyev G, Zurakowski D, Andrews NC. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 2007;109:4038-44.
26. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995;86:4446-53.
27. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-9.
28. Rivera S, Gabayan V, GanzT. Hepcidin contributes to the anemia of malignancy by sequestration iron in hepatic stores [abstract]. Blood 2004;104:3205.
29. Truksa J, Peng H, Lee P, Beutler E. Bone morphoge- netic proteins 2, 4, and 9 stimulate murine hepcidin 1expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci U S A 2006; 103:10289-93.
30. Babitt JŁ, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006;38:531 -9.
31. Wang RH, Li C, Xu X, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepci din expression. Cell Metab 2005;2:399-409.
32. Donovan KA, Lacy MO, Kline MP, et al. Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Leukemia 1998;12:593-600.
33. Urashima M, Ogata A, Chauhan D, et al. Transforming growth factor-ß1 differential effects on multiple myeloma versus normal B cells. Blood 1996:87:1928-38.